We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Elevated Levels of Defective Mitochondrial DNA Predict Likelihood of Reproductive Success

By LabMedica International staff writers
Posted on 14 Oct 2020
A sperm biomarker has been found that may be able to supplement or replace the semen parameters that poorly predict reproductive success yet are the most prevalent diagnostic tool for male infertility.

Mitochondrial DNA is maternally inherited, and sperm mitochondrial DNA copy number (mtDNAcn) typically decreases eight-to-10 fold during spermatogenesis to ensure that it is low upon fertilization. More...
Previous studies have shown that elevated sperm mitochondrial mtDNAcn and mitochondrial DNA deletions (mtDNAdel) were associated with decreased semen quality and lowered the odds of fertilization in men seeking fertility treatment.

To confirm this association, investigators at the University of Massachusetts Amherst (USA) determined sperm mtDNAcn and mtDNAdel from 384 semen samples using triplex probe-based quantitative PCR. Probability of pregnancy within one year was compared by mitochondrial DNA.

Results revealed that men with higher sperm mtDNAcn had as much as 50% lower odds of cycle-specific pregnancy and 18% lower probability of pregnancy within 12 months. The investigators stressed that the population examined in this study consisted primarily of Caucasian men and women and thus large diverse cohorts would be necessary to confirm the associations between sperm mtDNAcn and couple pregnancy success in other races/ethnicities.

"Clinically, the diagnosis of male infertility really has not changed in decades," said senior author Dr. Richard Pilsner, associate professor of public health and health sciences at the University of Massachusetts Amherst. "In the last 10 to 20 years, there have been major advances in the understanding of the molecular and cellular functions of sperm, but the clinical diagnosis has not changed or caught up. Understanding what is causing the retention of mitochondrial copy number during spermatogenesis will help us come up with better platforms to intervene and to promote better reproductive success. The logical next step was to determine if the associations between sperm mitochondrial biomarkers and fertilization among couples seeking infertility treatment could be extended to couples from the general population,"

The mitochondrial DNA study was published in the October 6, 2020, online edition of the journal Human Reproduction.

Related Links:
University of Massachusetts Amherst


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.